Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSCs in Parkinson's Disease
NCT07232147Phase 1Not yet recruiting
- Start
- Dec 2025
- Primary completion
- Oct 2027
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing IV + Nasal hUC-MSCs with IV hUC-MSCs + Nasal Placebo (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 48 weeks, Severity of Adverse Events at 48 weeks and 3 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07232147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232147.